Gland Pharma Ltd's Q3FY25 Quarter Results
- 04 Feb 2025
Result Summary
- Gland Pharma Ltd reported a 1.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 8.8%.
- Its expenses for the quarter were down by 5.4% QoQ and 12.0% YoY.
- The net profit increased 25.2% QoQ and increased 6.7% YoY.
- The earnings per share (EPS) of Gland Pharma Ltd stood at 12.4 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1442.55 | 1465.49 | 1582.55 | -1.6% | -8.8% |
Total Expenses | 1143.24 | 1208.72 | 1299.38 | -5.4% | -12.0% |
Profit Before Tax | 299.30 | 256.78 | 283.16 | 16.6% | 5.7% |
Tax | 94.61 | 93.25 | 91.30 | 1.5% | 3.6% |
Profit After Tax | 204.69 | 163.53 | 191.86 | 25.2% | 6.7% |
Earnings Per Share | 12.40 | 9.90 | 11.70 | 25.3% | 6.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Gland Pharma Ltd is a pharmaceutical company primarily involved in the development, manufacturing, and marketing of complex injectables. It serves the healthcare sector by providing affordable and innovative solutions in the generic injectables space. The company operates in a highly regulated industry with a focus on sterile injectables, oncology, and other specialized therapies. Gland Pharma has an established presence in several international markets, leveraging its manufacturing capabilities and compliance with global regulatory standards. Recent developments in the company may include expansions or strategic partnerships, though specific details are not available in the provided data.
Revenue
For the third quarter of the fiscal year 2025, Gland Pharma Ltd reported a total income of ₹1442.55 crores. This marks a decrease compared to ₹1465.49 crores in the previous quarter (Q2FY25) and ₹1582.55 crores in the same quarter of the previous year (Q3FY24). The quarter-over-quarter (QoQ) change in total income is a decrease of 1.6%, while the year-over-year (YoY) change is a decrease of 8.8%. These figures indicate changes in revenue streams that are quantified in the data.
Profitability
In Q3FY25, Gland Pharma Ltd achieved a profit before tax (PBT) of ₹299.30 crores, showing an increase from ₹256.78 crores in Q2FY25 and ₹283.16 crores in Q3FY24. The profit after tax (PAT) for this period was ₹204.69 crores, compared to ₹163.53 crores in the previous quarter and ₹191.86 crores in the same quarter of the previous year. The QoQ increase in PBT is 16.6%, and the YoY increase is 5.7%. The PAT saw a QoQ rise of 25.2% and a YoY increase of 6.7%. Earnings per share (EPS) were ₹12.40 in Q3FY25, reflecting a QoQ growth of 25.3% and a YoY growth of 6.0%. These metrics reflect the company's profitability performance over the specified periods.
Operating Metrics
Total expenses for Gland Pharma Ltd in Q3FY25 amounted to ₹1143.24 crores, which is a reduction from ₹1208.72 crores in Q2FY25 and ₹1299.38 crores in Q3FY24. The QoQ decrease in total expenses is 5.4%, while the YoY decrease is 12.0%. The tax expense for the quarter was ₹94.61 crores, slightly higher than ₹93.25 crores in Q2FY25 and ₹91.30 crores in Q3FY24, with a QoQ increase of 1.5% and a YoY increase of 3.6%. These operating metrics illustrate the company's cost management and tax liabilities within the specified timeframe.
